Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Cyteir Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| | | | | | | |
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
Equity | Common Stock, par value $0.001 per share | Other - 457(c) and 457(h) | 1,778,784 shares (2) | $1.65 (4) | $2,934,993.60 | $110.20 | $323.44 |
Equity | Common Stock, par value $0.001 per share | Other - 457(c) and 457(h) | 355,756 shares (3) | $1.65 (4) | $586,997.40 | $110.20 | $64.68 |
Total Offering Amounts | $3,521,991.00 | | $388.12 |
Total Fee Offsets | | | $0.00 |
Net Fee Due | | | $388.12 |
(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions.
(2)Represents an increase to the number of shares available for issuance under the Registrant’s 2021 Equity Incentive Plan, effective as of January 1, 2023. Shares available for issuance under the 2021 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on July 15, 2021 (Registration No. 333-257920).
(3)Represents an increase to the number of shares available for issuance under the Registrant’s 2021 Employee Stock Purchase Plan, effective as of January 1, 2023. Shares available for issuance under the ESPP Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on July 15, 2021 (Registration No. 333-257920).
(4)Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) based on the average of the high and low prices of the registrant’s Common Stock as reported on the Nasdaq Global Select Market on March 17, 2023 to be $1.71 and $1.59, respectively.
